Coridea, LLC
New York, NY
Company facts
- Self-certified in SAM.gov
- Entity structure
- Partnership or Limited Liability Partnership
- SAM.gov registration date
- Physical address
- 345 Park Ave S fl 3, New York, NY 10010, USA
- Website
- coridea.com
- Founded
- 2003
- Employees
- 1-10
- Industry
-
- Health Care
- Health Care Equipment & Services
- Health Care Providers & Services
- SIC code
- 38 Instruments & Related Products
- Profiles
Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .
Grant awards
Latest 5 listed here. See the rest on GovTribe.
Similar vendors
| Vendor | Location | Primary NAICS |
|---|---|---|
| Minnesota Healthsolutions Corporation | Minneapolis, MN | 541330 Engineering Services |
| Unandup, LLC | St. Louis, MO | 334510 Electromedical and Electrotherapeutic Apparatus Manufacturing |
| Starlight Cardiovascular, Inc. | San Diego, CA | 339112 Surgical and Medical Instrument Manufacturing |
| Mtti | West Chester, PA | 325413 In-Vitro Diagnostic Substance Manufacturing |
| Neurolux Inc. | Northfield, IL | 541714 Research and Development in Biotechnology (except Nanobiotechnology) |
About the company
Coridea, LLC is a New York City-based self-certified small disadvantaged business that develops minimally invasive medical device technologies for federal research funding, operating exclusively as a prime recipient on National Institutes of Health Small Business Innovation Research (SBIR) and cooperative agreement grants focused on neuromodulation and interventional cardiology applications.
Coridea's customer footprint is entirely concentrated within the Department of Health and Human Services National Institutes of Health, with nine awards from the National Heart, Lung, and Blood Institute (NHLBI), four from the National Institute on Drug Abuse (NIDA), two from the National Cancer Institute, and one from the National Institute of General Medical Sciences. The vendor has received $31.3 million in combined obligated funding across 16 awards since 2015, with all work performed as prime recipient rather than subcontractor.
The capability portfolio centers on transcutaneous and percutaneous neuromodulation systems addressing unmet clinical needs. Recent representative work includes a $305,365 Phase I SBIR award from NHLBI (awarded September 2026) to develop cooled radiofrequency bronchoscopic lung volume reduction technology for severe emphysema patients, addressing a clinical gap where surgical options and FDA-approved endobronchial valves exclude most candidates. A second $293,759 Phase I SBIR from NHLBI (August 2026) targets a closed-loop percutaneous stellate ganglion nerve stimulation system for hemodynamic support in septic shock, designed to reduce high-dose vasopressor requirements and associated complications in rural and underserved settings. Coridea also holds a multi-year $1.1 million Cooperative Agreement from NIDA (September 2023 through August 2028) to develop an automated external respiration system device for opioid-induced respiratory depression, modeled after automated external defibrillators for community deployment. Earlier Phase II work from NHLBI (May 2023 through April 2027) pursued high-intensity therapeutic ultrasound catheter development for obstructive hypertrophic cardiomyopathy septal reduction therapy. A Phase I award from the National Institute of General Medical Sciences (June 2024) validated stellate ganglion stimulation for septic shock hemodynamic support in preclinical models.
Activity has averaged less than one award per year over the past five years, with two awards in both 2021 and 2026 and single awards in 2023, 2024, and 2025. Five awards face ultimate completion within the next twenty-four months, creating recompete opportunity. Coridea holds prior support from NIDA and the National Institute of General Medical Sciences alongside its dominant NHLBI grant relationship, positioning the vendor as a specialized device-development recipient within the NIH SBIR ecosystem rather than a federal contractor operating under procurement vehicles.
Quick answers
Is Coridea, LLC registered in SAM.gov?
Yes. Coridea, LLC's SAM.gov registration is active through March 13, 2027.
What is Coridea, LLC's CAGE code?
Coridea, LLC's CAGE code is 71NT6, and its Unique Entity ID (UEI) is L5D8PHYBNJH7.
What is Coridea, LLC's most recent federal award?
Coridea, LLC's most recent federal grant award is Cooled RF bronchoscopic lung volume reduction (R43HL186091), from National Heart Lung and Blood Institute (NIH), on September 1, 2026.
On GovTribe
See Coridea, LLC's full federal record
- Federal grant awards
- Funding analysis by agency, NAICS and set-aside
- Similar vendors